Here are four things to know.
1. The patch, ZTlido, was approved for postherpetic neuralgia, a common complication of shingles characterized by burning pain.
2. While there are no FDA-approved opioids to treat postherpetic neuralgia, they are commonly prescribed to manage pain.
3. ZTlido is manufactured by Sorrento Therapeutics. After the drugmaker announced its product received FDA approval, its shares soared 18.3 percent, according to the report.
4. The FDA previously rejected ZTlido in 2016.
More articles on supply chain:
Why a better hospital supply chain starts with better relationships
Teva shutters offices in New York City, Washington D.C., as part of cost cutting plan
Walgreens, AmerisourceBergen reportedly end takeover discussions with no deal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.